Profiles of Drug Substances, Excipients, and Related Methodology, Volume 49 provides timely and pertinent information on a variety of timely topics, including Physical Profiles of Drug Substances and Excipients; Analytical Profiles of Drug Substances and Excipients; ADME Profiles of Drug Substances and Excipients; Methodology Related to the Characterization of Drug Substances and Excipients; and Methods of Chemical Synthesis. In addition, it includes comprehensive profiles of five drug compounds: Deferasirox, Duvelisib, Regorafenib, Ponatinib and Avanafil. Finally, the book contains a chapter on Regulation and Standardization of Herbal Drugs: Current status, Limitation, Challenge’s, and Future Prospectives.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Series Page - p. iii 5. Copyright - p. iii 6. Contributors - p. iii 7. Preface - p. iii 8. Chapter One: Deferasirox: A comprehensive drug profile - p. 2 9. Chapter Two: Duvelisib: A comprehensive profile - p. 20 10. Chapter Three: Regorafenib: A comprehensive drug profile - p. 42 11. Chapter Four: Ponatinib: A comprehensive drug profile - p. 83 12. Chapter Five: Avanafil: A comprehensive drug profile - p. 116 13. Chapter Six: Regulation and standardization of herbal drugs: Current status, limitation, challenge’s and future prospective - p. 154 14. Cumulative index - p. 197
Profiles of Drug Substances, Excipients, and Related Methodology, Volume 49 provides timely and pertinent information on a variety of timely topics, including Physical Profiles of Drug Substances and Excipients; Analytical Profiles of Drug Substances and Excipients; ADME Profiles of Drug Substances and Excipients; Methodology Related to the Characterization of Drug Substances and Excipients; and Methods of Chemical Synthesis. In addition, it includes comprehensive profiles of five drug compounds: Deferasirox, Duvelisib, Regorafenib, Ponatinib and Avanafil. Finally, the book contains a chapter on Regulation and Standardization of Herbal Drugs: Current status, Limitation, Challenge’s, and Future Prospectives.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Series Page - p. iii 5. Copyright - p. iii 6. Contributors - p. iii 7. Preface - p. iii 8. Chapter One: Deferasirox: A comprehensive drug profile - p. 2 9. Chapter Two: Duvelisib: A comprehensive profile - p. 20 10. Chapter Three: Regorafenib: A comprehensive drug profile - p. 42 11. Chapter Four: Ponatinib: A comprehensive drug profile - p. 83 12. Chapter Five: Avanafil: A comprehensive drug profile - p. 116 13. Chapter Six: Regulation and standardization of herbal drugs: Current status, limitation, challenge’s and future prospective - p. 154 14. Cumulative index - p. 197
